MIGRAINE headaches cost the Australian economy almost $36 billion annually, according to a new report prepared for Novartis Australia which will be released today in Canberra.
The Deloitte Access Economics "Migraine in Australia Whitepaper" is claimed to be the first time the economic cost of the condition has been tabulated.
It reveals that the number of Australians who suffer from migraine headaches now stands at 4.9 million, with the economic burden comprising $16.3 billion in lost productivity along with $14.3 billion in health system costs.
More than twice as many women as men suffer from migraine (28.7% versus 12%), while the vast majority (86%) of sufferers are of working age, with some losing up to 30 productive working days per year.
The report's release follows the recent Australian registration of Novartis' Aimogiv (erenumab) (PD 23 Aug) which is a novel migraine prophylaxis treatment targeting the calcitonin gene-related peptide.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Oct 18
